Sol-Gel has positive results in trials of rosacea treatment

Sol-Gel Technologies Ltd. shares SLGL, +13.16% soared 9.5% in premarket trade Monday, after the company said that two late-stage trials of a treatment for papulopustular rosacea produced positive results. The Israeli company said the trials evaluating Epsolay(R) microencapsulated benzoyl peroxide cream, 5%, made with the company’s proprietary microencapsulation technology, met its main goals. Epsolay showed statistically significant improvement in both primary endpoints of the number of patients achjieving “clear” or “almost clear” in the Investigator Global Assessment (IGA) and absolute mean reduction from baseline in inflammatory lesion count, the company said in a statement. Papulopustular rosacea is a chronic inflammatory skin disorder that affects nearly 5 million Americans. Symptoms include redness on the cheeks, nose, chin or forehead and over time, it can cause pimples, burning, stinging, dry skin, plagues and skin thickening. Shares have gained 51.5% in 2019, while the S&P 500 SPX, -0.60% has gained 19.3%

https://www.marketwatch.com/story/sol-gel-technologies-reports-positive-results-in-trials-of-treatment-for-papulopustular-rosacea-2019-07-08-7912256